search
Back to results

Intrawound Vancomycin Powder in Spinal Fusion Surgery (iVRCT)

Primary Purpose

Spinal Fusion Acquired

Status
Completed
Phase
Phase 4
Locations
Austria
Study Type
Interventional
Intervention
Vancomycin
Sponsored by
Orthopedic Hospital Vienna Speising
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Spinal Fusion Acquired focused on measuring spinal fusion, topical antibiotics, vancomycin, surgical site infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Planned TLIF (transforaminal lumbar interbody fusion) or PLIF (posterolateral lumbar interbody fusion) surgery
  • TLIF/PLIF fusion length of one or two motion-segments OR
  • One motion-segment TLIF/PLIF in conjunction with one motion-segment decompression surgery or microscopic disc surgery (microdiscectomy)
  • Fusions within L1 (first lumbar vertebra) through S1 (sacrum)
  • Age of 18-years or older
  • Signed informed consent

Exclusion Criteria:

  • Preoperative inflammatory or infectious state (C-reactive protein levels above 10mg/l)
  • Allergic to vancomycin, teicoplanin or penicillin
  • Preexisting auto-immune disease with an impaired immune system
  • Current post-traumatic vertebral injury (e.g. vertebral split fracture)
  • Preexisting Renal impairment
  • Preexisting cochlea damage
  • Pregnancy

Sites / Locations

  • Orhopedic Hospital Speising

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control Group

Vancomycin Group

Arm Description

No additional treatment. Routine iv. antibiotic prophylaxis only.

Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged

Outcomes

Primary Outcome Measures

SSI rate
Rate of superficial and deep surgical site infections (according to CDC criteria)

Secondary Outcome Measures

C-reactive protein
Course of postoperative CRP levels
Revision rate
Revision rate due to surgical site infections

Full Information

First Posted
December 12, 2015
Last Updated
March 2, 2021
Sponsor
Orthopedic Hospital Vienna Speising
search

1. Study Identification

Unique Protocol Identification Number
NCT02631408
Brief Title
Intrawound Vancomycin Powder in Spinal Fusion Surgery
Acronym
iVRCT
Official Title
Application of Intrawound Vancomycin Powder to Reduce Surgical Site Infections in Spinal Fusion Surgery - A Prospective, Randomized, Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
August 2015 (undefined)
Primary Completion Date
March 1, 2019 (Actual)
Study Completion Date
March 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Orthopedic Hospital Vienna Speising

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Vancomycin powder (for solution for Infusion) will be investigated (off-label usage) in spinal fusion surgery. The powder will be locally administered into to the wound cavity before wound closure. Hypothesis: Locally applied vancomycin powder leads to a reduction in postoperative surgical site infections
Detailed Description
Vancomycin is being widely used as an antibiotic agent for intravenous and topical use. The surgical application of vancomycin powder in Austria is limited as there is no powder with marketing authorization for intraoperative, intrawound usage. Previous reports widely document the application of vancomycin powder for solution for infusion. The powder is not soluted, but instead directly spread throughout the wound surface. Limited data is available for spinal fusion surgery, mostly retrospective studies. Results were promising, but the low evidence level does not allow for a conclusion regarding routine usage. Additional randomized, controlled trials are necessary to further investigate this matter. This trial aims to investigate Vancomycin powder "Xellia" 1000mg, which has a Marketing authorization, in an off-label usage (intrawound, intraoperatively) in spinal fusion surgery. The investigational medicinal product will be used unmodified.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Fusion Acquired
Keywords
spinal fusion, topical antibiotics, vancomycin, surgical site infection

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
308 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control Group
Arm Type
No Intervention
Arm Description
No additional treatment. Routine iv. antibiotic prophylaxis only.
Arm Title
Vancomycin Group
Arm Type
Experimental
Arm Description
Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged
Intervention Type
Drug
Intervention Name(s)
Vancomycin
Other Intervention Name(s)
Vancomycin Hydrochloride, Powder for Solution for Infusion
Intervention Description
Locally, intrawound applied vancomycin powder
Primary Outcome Measure Information:
Title
SSI rate
Description
Rate of superficial and deep surgical site infections (according to CDC criteria)
Time Frame
1 year
Secondary Outcome Measure Information:
Title
C-reactive protein
Description
Course of postoperative CRP levels
Time Frame
7 days
Title
Revision rate
Description
Revision rate due to surgical site infections
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Planned TLIF (transforaminal lumbar interbody fusion) or PLIF (posterolateral lumbar interbody fusion) surgery TLIF/PLIF fusion length of one or two motion-segments OR One motion-segment TLIF/PLIF in conjunction with one motion-segment decompression surgery or microscopic disc surgery (microdiscectomy) Fusions within L1 (first lumbar vertebra) through S1 (sacrum) Age of 18-years or older Signed informed consent Exclusion Criteria: Preoperative inflammatory or infectious state (C-reactive protein levels above 10mg/l) Allergic to vancomycin, teicoplanin or penicillin Preexisting auto-immune disease with an impaired immune system Current post-traumatic vertebral injury (e.g. vertebral split fracture) Preexisting Renal impairment Preexisting cochlea damage Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philipp Becker, MD
Organizational Affiliation
Orthopedic Hospital Speising
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lukas Panzenboeck, MD
Organizational Affiliation
Orthopedic Hospital Speising
Official's Role
Study Chair
Facility Information:
Facility Name
Orhopedic Hospital Speising
City
Vienna
ZIP/Postal Code
1130
Country
Austria

12. IPD Sharing Statement

Learn more about this trial

Intrawound Vancomycin Powder in Spinal Fusion Surgery

We'll reach out to this number within 24 hrs